Cancer Gene Therapy

Preclinical Efficacy Reported for Therapeutic Virus

Published in Cancer Weekly, December 7th, 1998

Researchers at Onyx Pharmaceuticals, Inc., Richmond, California, have developed a second viral therapeutic that replicates in and destroys cancer cells while leaving resting normal cells relatively unharmed.

This virus, ONYX-838, is genetically engineered to replicate in and destroy tumor cells that have defects in the retinoblastoma (RB) gene pathway. Defects in the RB gene pathway are present in virtually all human cancers.

"The RB-targeted virus showed substantial efficacy in several mouse tumor models," said David H. Kirn, MD, Onyx. Kirn presented the results at the Seventh International Conference on Gene Therapy of Cancer, held in San Diego,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1998-12-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry